Harvest One Cannabis Inc. (TSXV:HVST) ("Harvest One") through its wholly owned Swiss Subsidiary Satipharm AG ("Satipharm") is pleased to advise that results from the Phase 1 Clinical Trial undertaken by PhytoTech Therapeutics ("PTL") in Israel, using Satipharm’s proprietary GelpellR technology have been published.

The article “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology” has been published in Clinical Pharmacology in Drug Development (“CPDD”).

The PTL101 drug beads utilise a proprietary formulation developed through Satipharm’s Gelpell-CBD™ product technology, which contain organically derived, highly purified CBD.

Established in 2012, CPDD is an international, peer-reviewed publication and the official journal of the American College of Clinical Pharmacology, providing a forum for the presentation of first-time-in-man study results. CPDD publishes high-quality clinical pharmacology studies in drug development which are primarily (but not exclusively) performed in early development phases in healthy subjects.

PTL completed its Phase 1 Clinical Trial of the PTL101 capsules in March 2016, with results demonstrating the safety and high performance of the oral capsule technology, including the effective delivery profile of cannabidiol (“CBD”) compound to trial subjects.

The Phase 1 Clinical Trial also highlighted the favourable bioavailability of the capsules in comparison to Sativex – a market-leading, commercially available cannabinoid oral spray produced by GW Pharmaceuticals (LON: GWP) (NASDAQ: GWPH).

Phase 2 Clinical Trial Update

PTL has since commenced its Phase 2 Clinical Trial into the efficacy of the PTL101 capsules in treating refractory epilepsy in children.

The completion of this Phase 2 Clinical Trial would be a major catalyst towards the commercial development of the PTL101 capsules, with PTL potentially only the third company behind GW Pharmaceuticals and Insys Therapeutics Inc. (NASDAQ: INSY) to present results of a formal Phase 2 Clinical Trial into refractory epilepsy in children.

In addition, a Phase 2 Clinical Trial into the safety and efficacy of PTL201 capsules in treating spasticity related symptoms of multiple sclerosis (“MS”) patients is planned to commence in due course.

About Harvest One

Harvest One Cannabis Inc. (TSXV: HVST) controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation and sales license, making Harvest One one of only a few companies globally with the capacity to commercially cultivate and sell cannabis in a federally regulated environment.

For more information on Harvest One Cannabis, please contact:

Colin Clancy
Investor Relations
+ 1 (877) 915 7934
cclancy@mmj.ca

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.